Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/CDH1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CDH1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CDH1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/CDH1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CDH1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/CDH1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CDH1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/CDH1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CDH1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/CDH1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CDH1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CDH1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00511694 | Colorectum | FAP | nuclear transport | 77/2622 | 301/18723 | 6.15e-08 | 4.54e-06 | 77 |
GO:00071603 | Colorectum | FAP | cell-matrix adhesion | 63/2622 | 233/18723 | 1.13e-07 | 7.43e-06 | 63 |
GO:00313344 | Colorectum | FAP | positive regulation of protein-containing complex assembly | 62/2622 | 237/18723 | 5.03e-07 | 2.61e-05 | 62 |
GO:00725944 | Colorectum | FAP | establishment of protein localization to organelle | 96/2622 | 422/18723 | 6.63e-07 | 3.20e-05 | 96 |
GO:00072652 | Colorectum | FAP | Ras protein signal transduction | 80/2622 | 337/18723 | 9.61e-07 | 4.33e-05 | 80 |
GO:00323884 | Colorectum | FAP | positive regulation of intracellular transport | 53/2622 | 202/18723 | 2.99e-06 | 1.10e-04 | 53 |
GO:19011842 | Colorectum | FAP | regulation of ERBB signaling pathway | 27/2622 | 79/18723 | 4.77e-06 | 1.57e-04 | 27 |
GO:00019543 | Colorectum | FAP | positive regulation of cell-matrix adhesion | 22/2622 | 58/18723 | 5.19e-06 | 1.68e-04 | 22 |
GO:00975814 | Colorectum | FAP | lamellipodium organization | 29/2622 | 90/18723 | 8.11e-06 | 2.40e-04 | 29 |
GO:00420582 | Colorectum | FAP | regulation of epidermal growth factor receptor signaling pathway | 25/2622 | 73/18723 | 1.02e-05 | 2.93e-04 | 25 |
GO:00468224 | Colorectum | FAP | regulation of nucleocytoplasmic transport | 32/2622 | 106/18723 | 1.30e-05 | 3.53e-04 | 32 |
GO:00903164 | Colorectum | FAP | positive regulation of intracellular protein transport | 43/2622 | 160/18723 | 1.30e-05 | 3.53e-04 | 43 |
GO:00016673 | Colorectum | FAP | ameboidal-type cell migration | 100/2622 | 475/18723 | 1.42e-05 | 3.79e-04 | 100 |
GO:00508083 | Colorectum | FAP | synapse organization | 91/2622 | 426/18723 | 1.90e-05 | 4.74e-04 | 91 |
GO:00323864 | Colorectum | FAP | regulation of intracellular transport | 75/2622 | 337/18723 | 2.38e-05 | 5.60e-04 | 75 |
GO:00301003 | Colorectum | FAP | regulation of endocytosis | 52/2622 | 211/18723 | 2.47e-05 | 5.77e-04 | 52 |
GO:00457854 | Colorectum | FAP | positive regulation of cell adhesion | 92/2622 | 437/18723 | 3.09e-05 | 7.04e-04 | 92 |
GO:00331574 | Colorectum | FAP | regulation of intracellular protein transport | 55/2622 | 229/18723 | 3.20e-05 | 7.20e-04 | 55 |
GO:00345044 | Colorectum | FAP | protein localization to nucleus | 66/2622 | 290/18723 | 3.47e-05 | 7.64e-04 | 66 |
GO:00070434 | Colorectum | FAP | cell-cell junction assembly | 39/2622 | 146/18723 | 3.74e-05 | 8.09e-04 | 39 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CDH1 | SNV | Missense_Mutation | | c.727N>A | p.Glu243Lys | p.E243K | P12830 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A1-A0SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDH1 | SNV | Missense_Mutation | rs587782623 | c.2600A>G | p.Asn867Ser | p.N867S | P12830 | protein_coding | tolerated(0.43) | benign(0.264) | TCGA-A2-A1G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
CDH1 | SNV | Missense_Mutation | | c.727N>A | p.Glu243Lys | p.E243K | P12830 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A091-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | PD |
CDH1 | SNV | Missense_Mutation | | c.727N>A | p.Glu243Lys | p.E243K | P12830 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A0A7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CDH1 | SNV | Missense_Mutation | | c.846N>T | p.Met282Ile | p.M282I | P12830 | protein_coding | tolerated(0.18) | probably_damaging(0.922) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CDH1 | SNV | Missense_Mutation | novel | c.1316C>A | p.Ala439Glu | p.A439E | P12830 | protein_coding | tolerated(0.06) | benign(0.398) | TCGA-AO-A03T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
CDH1 | SNV | Missense_Mutation | rs587782024 | c.2450N>T | p.Ala817Val | p.A817V | P12830 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
CDH1 | SNV | Missense_Mutation | novel | c.493N>C | p.Glu165Gln | p.E165Q | P12830 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AR-A2LJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
CDH1 | SNV | Missense_Mutation | | c.832N>A | p.Gly278Arg | p.G278R | P12830 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
CDH1 | SNV | Missense_Mutation | | c.779N>A | p.Pro260His | p.P260H | P12830 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0BA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
999 | CDH1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Volasertib | VOLASERTIB | 26597303 |
999 | CDH1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Erlotinib | ERLOTINIB | 26251290 |
999 | CDH1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Selumetinib | SELUMETINIB | 26251290 |
999 | CDH1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | N/A | | 26182300,26380059 |
999 | CDH1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | PROTEOLYTIC ENZYMES | | 2211831 |
999 | CDH1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Capecitabine | CAPECITABINE | 26487584 |
999 | CDH1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | BI2536 | | 26597303 |
999 | CDH1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | ANTISERUM | | 3880756 |
999 | CDH1 | CLINICALLY ACTIONABLE, DRUGGABLE GENOME | | Lapatinib | LAPATINIB | 26487584 |